US · Healthcare · Biotechnology
Analysts rate Nanobiotix a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $53.93.
| Fund | Stake |
|---|---|
| Johnson & Johnson | 11.04% |
| Morgan Stanley - Brokerage Accounts | 0.10% |
| Jane Street Group LLC | 0.06% |
| HRT FINANCIAL LLC | 0.05% |
| XTX Topco Ltd | 0.03% |
| Optiver Holding B.V. | 0.03% |
| Marshall Wace Asset Management Ltd | 0.02% |
| Citadel Advisors Llc | 0.01% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • Nanobiotix S.A. filed a Form 6-K with the SEC for October 2026. • On October 1, 2026, the company issued a press release, fil | 2026-10-01 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Total revenue and other income fell to €5.551 million in H1 2026 from €26.638 million in H1 2025, largely because H1 2025 included | 2026-09-24 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Nanobiotix S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission for September 2026. • The filing states tha | 2026-09-24 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Nanobiotix S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission for September 2026. • The filing reports th | 2026-09-22 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Nanobiotix S.A. filed a Form 6-K with the SEC for September 2026. • The filing reports that the company issued a press releas | 2026-09-14 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Nanobiotix filed its annual report for the fiscal year ended December 31, 2025, under IFRS Accounting Standards. • The company ha | 2026-03-31 |
| Annual report FY2024 (20-F) | 2025-04-02 |
| Annual report FY2023 (20-F) | 2024-04-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nanobiotix — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.